Overview

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Status:
Completed

Trial end date:
2019-06-24

Target enrollment:

Participant gender:

Summary

This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Collaborator:

European Organisation for Research and Treatment of Cancer - EORTC

Treatments:

Dacarbazine
Lomustine
Temozolomide